Gelteq shares surge 65.05% intraday on positive preclinical CBD bioavailability results and accelerated market entry prospects.

Gelteq surged 65.05% intraday after announcing preclinical results demonstrating its proprietary oral gel platform significantly enhances CBD bioavailability by over 22% compared to an FDA-approved oil-based product, despite using a lower CBD concentration. The findings validate the platform’s potential to deliver lipophilic cannabinoids more efficiently, creating a pathway for expedited market entry in Australia via the Special Access Scheme. This development positions Gelteq to accelerate expansion into global medicinal cannabis markets, directly aligning with the stock’s sharp intraday rally.